Sequential Quantification of Viral Load in the Upper Respiratory Tract in Adult Patients Admitted for Influenza and Treated With Olsetamivir
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- The duration of influenza virus carriage in the upper airways in patients treated with olsetamivir will be observed
研究概览
简要总结
Seasonal influenza is a frequent disorder with high impact on morbidity and mortality and significant burden on healthcare-related cost. In France, the 2018-2019 flu epidemic has led to 13,100 all-cause death including 9,900 death directly related to the viral infection.
As cross-transmission of influenza is responsible for nosocomial outbreaks, preventing transmission of infectious agents in healthcare settings is a major issue. If vaccination of patients and healthcare givers remains cornerstone, control procedures are mandatory. Therefore patients admitted with influenza require isolation precautions including admission in a single room and protective measures. Based on experts advise, isolation is currently recommended for 5 to 8 days. Duration of isolation depends on immune status and antiviral therapy. However, during periods of epidemic, every hospital room is valuable and each ressource has to be tightly used. Risk of contamination is related to the presence of influenza in the upper airways. To the Promoteur 's knowledge, presence of influenza in the upper airways has not been studied in patients receiving oseltamivir. The question is : Do duration of isolation in patients admitted with flu decreas when they are treated with antiviral therapy. To answer this question The Promoteur would aim to determine influenza carriage in the upper airways in in-patients treated by olsetamivir.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients (≥18 years)
- •Positive testing for influenza (A or B)
- •Patients hospitalized and treated with olsetamivir
- •Signature of informed consent
- •Affiliation to healthcare insurance (France, Monaco)
排除标准
- •Refusal to participate
- •Admission to intensive care
- •Palliative care
- •Unable to give inform consent
- •Patients under legal protection
结局指标
主要结局
The duration of influenza virus carriage in the upper airways in patients treated with olsetamivir will be observed
时间窗: Within 8 days following patient's participation
次要结局
- Duration of influenza virus carriage in the upper airways among patients treated with olsetamivir according to the viral strand (A or B) will be mesured(Within 8 days following patient's participation)
- Duration of influenza virus carriage in the upper airways among patients treated with olsetamivir according to their vaccination status and comorbidities will be mesured and compared(Within 8 days following patient's participation)
- Difference in the number of days in isolation in patients hospitalized and treated with olsetamivir will be evaluated(21 months)
